Loading
Adding the AKT inhibitor ipatasertib to first-line paclitaxel lengthened the time before metastatic triple-negative cancer grew from 4.9 to 6.2 months, the first randomised support for AKT-directed therapy in the disease.
124 women with untreated inoperable locally advanced or metastatic TNBC were randomised to paclitaxel 80 mg/m2 with ipatasertib 400 mg or placebo, stratified by prior therapy, chemotherapy-free interval and tumour PTEN status. Median progression-free survival was 6.2 versus 4.9 months (stratified HR 0.60, 95% CI 0.37 to 0.98) in the intention-to-treat population and 6.2 versus 3.7 months (HR 0.59, 0.26 to 1.32) in the 48 PTEN-low patients. Grade 3 or worse diarrhoea occurred in 23% with ipatasertib.
LOTUS and PAKT together made the PI3K/AKT/PTEN-altered subgroup the target population for AKT inhibitors in TNBC; the phase 3 IPATunity130 later failed to confirm it, which is why no AKT inhibitor is approved here.
Shares Ipatasertib, PTEN, AKT, PI3K / AKT / mTOR.
Shares Ipatasertib, PTEN, AKT, PI3K / AKT / mTOR.
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, AKT, PI3K / AKT / mTOR.
Shares PTEN, AKT, PI3K / AKT / mTOR, Metastatic triple-negative breast cancer.
Shares Ipatasertib, AKT, Roche / Genentech, Paclitaxel / nab-paclitaxel.
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares PTEN alteration (sequencing) and PTEN loss (IHC), PTEN, PI3K / AKT / mTOR, Triple-negative breast cancer (TNBC).
Shares Ipatasertib, Roche / Genentech.